Barclays Maintains Overweight on CSX, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Brandon Oglenski maintains an Overweight rating on CSX but lowers the price target from $41 to $40.

September 25, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Brandon Oglenski maintains an Overweight rating on CSX but lowers the price target from $41 to $40, indicating a slight adjustment in expectations.
The Overweight rating suggests continued confidence in CSX's performance, but the slight reduction in the price target from $41 to $40 indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price as the overall positive outlook remains.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100